Daxxify
DaxibotulinumtoxinA | 6+ months of sustained effect
이 치료에 대해
Daxxify (Revance Therapeutics, USA) is DaxibotulinumtoxinA with peptide-derived stabilization components. Key feature: sustained effect 6+ months (average 7.5-9 months) vs traditional 3-4 months—significant patient convenience improvement.
FDA cosmetic approval in 2023, newest generation. Long-lasting effect reduces treatment frequency and cost burden. Improved stability for storage and transport conditions.
작용 기전
DaxibotulinumtoxinA combines BoNT-A toxin with peptide-based stabilizers, slowing post-injection toxin degradation and extending SNAP-25 action duration. Results in 3-4× longer effect persistence than traditional products. May also slow nerve terminal regeneration.
적응증
기대 효과
Onset 3-5 days, peak 2-4 weeks. Duration 6+ months (average 7.5-9 months) long-lasting. Patients transition from traditional 3-4 month treatments to 6-9 month intervals, reducing annual injections ~50%.
임상 근거
위험 및 부작용
Injection pain/swelling/bruising. Brow ptosis and dry eye similar to traditional products. Long duration means adverse effects may persist longer than 3-4 months. Conservative dosing recommended for first treatment.